Jennifer C Golden

US Patent:

20130345277, Dec 26, 2013

Filed:

Apr 22, 2013

Appl. No.:

13/867658

Inventors:

Kansas University Center for Technology Commercialization, Inc. - , US
Zurab Surviladze - Albuquerque NM, US
Tudor Oprea - Albuquerque NM, US
Laurie Hudson - Albuquerque NM, US
Jeffrey Aube - Lawrence KS, US
Jennifer E. Golden - Olathe KS, US
Chad E. Schroeder - Lawrence KS, US
Denise S. Simpson - Lawrence KS, US
Julica J. Noth - Munich, DE

Assignee:

Kansas University Center for Technology Commercialization, Inc. - Lawrence KS
STC.UNM - Albuquerque NM

International Classification:

A61K 31/415
A61K 45/06
C07D 231/06

US Classification:

514403, 5483797

Abstract:

The present invention relates to molecules which function as selective modulators of the Ras-homologous (Rho) family of small GTPases, in particular, Cdc42 GTPase and their use to treat diseases, for example cancers, including metastatic cancer, genetic and acquired diseases where activation of Cdc42 GTPase plays a pivotal role, such as neurodegenerative diseases, rheumatoid arthritis, atherosclerosis, diabetes type I, autosomal polycystic kidney disease, cystic kidney disease, precystic kidney disease, microbial infections, including infections, infections, infections and its secondary effects including gastric ulcers, (Q-fever) infections and infections, fungal infections including and and their secondary effects including lung edema. Additionally, compounds according to the present invention may be used to inhibit rejection in transplant patients (pursuant to transplantation), to promote immunosuppression, anti-inflammatory response and to mobilize stem cell (migration) in patients in need, among others.

US Patent:

20160244457, Aug 25, 2016

Filed:

May 5, 2016

Appl. No.:

15/147648

Inventors:

- Lawrence KS, US
- Albuquerque NM, US
Bruce S. Edwards - Albuquerque NM, US
Juan Jacob Strouse - Albuquerque NM, US
Hadya M. Khawaja - Albuquerque NM, US
Jerec Warren Ricci - Albuquerque NM, US
Jeffrey Aube - Lawrence KS, US
Jennifer Elizabeth Golden - Olathe KS, US
Warren S. Weiner - Lawrence KS, US
Chad E. Schroeder - Lawrence KS, US

International Classification:

C07D 487/04
A61K 31/4745
A61K 31/519

Abstract:

The present invention provides novel compounds which inhibit cancer-associated transporter proteins, methods of treating or preventing the onset of a cancer-associated transporter protein-mediated disease by administering such compounds, and pharmaceutical compositions comprising such compounds. In one embodiment, the invention provides novel pyrazolo[1,5-a]pyrimidine efflux inhibitors that are selective toward ABCG2 over ABCB1.

US Patent:

20150197526, Jul 16, 2015

Filed:

Dec 31, 2014

Appl. No.:

14/587925

Inventors:

- Albuquerque NM, US
- Lawrence KS, US
Bruce S. Edwards - Albuquerque NM, US
Juan Jacob Strouse - Albuquerque NM, US
Hydya M. Khawaja - Albuquerque NM, US
Jerec Warren Ricci - Albuquerque NM, US
Jeffrey Aube - Lawrence KS, US
Jennifer Elizabeth Golden - Olathe KS, US
Tuanli Yao - Lawrence KS, US
Warren S. Weiner - Lawrence KS, US
Chad E. Schroeder - Lawrence KS, US

International Classification:

C07D 487/04
A61K 31/4745
A61K 45/06
A61K 31/519

Abstract:

The present invention provides novel compounds which inhibit cancer-associated transporter proteins, methods of treating or preventing the onset of a cancer-associated transporter protein-mediated disease by administering such compounds, and pharmaceutical compositions comprising such compounds. In one embodiment, the invention provides novel pyrazolo[1,5-a]pyrimidine efflux inhibitors that are selective toward ABCG2 over ABCB1.

US Patent:

20140248268, Sep 4, 2014

Filed:

May 15, 2014

Appl. No.:

14/278468

Inventors:

Larry Sklar - Albuquerque NM, US
Jacob Agola - Albuquerque NM, US
Zurab Surviladze - Albuquerque NM, US
Jeffrey Aube - Lawrence KS, US
Jennifer Golden - Olathe KS, US
Chad E. Schroeder - Lawrence KS, US
Denise S. Simpson - Lawrence KS, US

International Classification:

C07D 495/04
A61K 45/06
A61K 31/381

US Classification:

4241331, 514443, 514274, 424649, 4241431

Abstract:

This invention relates to compounds and their use as inhibitors or activators of Rab7 GTPase to treat or prevent the onset of Rab 7 GTPase-associated disorders such as neuropathies, cancer, metabolic diseases of bone and lipid storage. The invention is also applicable to infectious diseases where Rab7 is inactivated or its protein-protein interactions are modulated to facilitate intracellular survival of pathogens. The compound described acts as a competitive inhibitor of nucleotide binding and as such also has utility as a scaffold for targeting other small GTPases. In one aspect, methods of treatment of the invention are used to treat or prevent the onset of hereditary sensory neuropathies such as Charcot-Marie-Tooth type 2B disease. Related pharmaceutical compositions, assays, and drug screens are also provided.